چكيده لاتين :
Iran is a developing country in Middle East which has experienced some political
and economical turbulence during the past decades. Government ofIran, after the 1979
Islamic revolution, has devoted considerable resources on national health, including
the pharmaceutical sector. As a result, health indicators have improved substantially
over the past two decades and the availability and affordability of medicines have also
been greatly improved. In order to fulfill the MOH mission in providing access to a
sufficient quantity of safe, effective and high quality medicines that are affordable
for all population, after the 1979 Islamic revolution Iran has adopted a full generic
based medicine system and local production of medicines and vaccines has become
one of the main goals of the national drug policy. Government of Iran has invested
considerably on the pharmaceutical industry over the past decades. However, it
seems that this investment, mainly due to the lack of R&D activities and unanimous
subsidies, has not been proportionately fruitful for Iranיs health system. Iran drug
market, especially in recent years, experienced a sharp growth and in 2004 the value
of the market, including direct government subsidies to the imported medicines,
became over USD1.2bn. The market has increased annually, on average more than
30% , during 1993-2003.
